A5068815275- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Radiopharmaceutical Chemistry and Applications
- Immunotherapy and Immune Responses
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- PARP inhibition in cancer therapy
- Gyrotron and Vacuum Electronics Research
- Epigenetics and DNA Methylation
- Hedgehog Signaling Pathway Studies
- Meningioma and schwannoma management
- Cancer Cells and Metastasis
- Microtubule and mitosis dynamics
- Renal and related cancers
- Cancer therapeutics and mechanisms
- RNA modifications and cancer
- Neonatal Health and Biochemistry
- Pancreatic and Hepatic Oncology Research
- Cancer, Lipids, and Metabolism
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
Harvard University
2022-2023
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
2023
University Medical Center of the Johannes Gutenberg University Mainz
2017-2021
Johannes Gutenberg University Mainz
2017-2021
Columbia University
2020
University Hospital Frankfurt
1996
Goethe University Frankfurt
1996
Klinik und Poliklinik für Nuklearmedizin
1993
Highlights•3F3-FMA is identified in a screen as selective ferroptosis-immunostaining reagent•The antigen of 3F3-FMA the transferrin receptor 1 protein (TfR1)•Anti-TfR1 antibodies can detect ferroptosis by immunofluorescence and flow cytometry•Anti-TfR1 anti-MDA xenograft cancer modelsSummaryFerroptosis type regulated cell death driven iron-dependent accumulation oxidized polyunsaturated fatty acid-containing phospholipids. There no reliable way to selectively stain ferroptotic cells tissue...
In 2006, Children's Oncology Group (COG) reclassified subgroups of toddlers diagnosed with neuroblastoma from high-risk to intermediate-risk, when the age cutoff for assignment was raised 365 days (12 months) 547 (18 months). The primary aim this retrospective study determine if excellent outcome maintained after assigned reduction therapy.
High-grade neuroepithelial tumor of the central nervous system with BCOR alteration (HGNET-BCOR) is a rare, highly malignant tumor. At time this publication, no standard protocol exists to treat entity. In work, we tested responsiveness primary culture PhKh1 derived from tissue pediatric HGNET-BCOR patient (P1) inhibitors Sonic hedgehog pathway combined radiation. The SMO vismodegib and itraconazole had low effect on proliferation cells. However, GLI inhibitor arsenic trioxide reduced...
(1) Background: The high-grade neuroepithelial tumor of the central nervous system with BCOR alteration (HGNET-BCOR) is a highly malignant tumor. Preclinical models and molecular targets are urgently required for this cancer. Previous data suggest potential role insulin-like growth factor (IGF) signaling in HGNET-BCOR. (2) Methods: primary HGNET-BCOR cells PhKh1 were characterized by western blot, copy number variation, methylation analysis electron microscopy. expression IGF2 IGF1R was...
The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing blood–brain barrier remains a significant obstacle for clinical translation. Here, we targeted IGF using ceritinib, off-target inhibitor IGF1 receptor (IGF1R) and insulin (INSR), pediatric patient with unclassified notch 1 (NOTCH1) germline mutation. Pathway analysis revealed activation sonic hedgehog (SHH), wingless integrated-1 (WNT), IGF, Notch...
Medulloblastoma is the most common malignant brain tumor in children. Immunotherapy yet to demonstrate dramatic results medulloblastoma, one reason being low rate of mutations creating new antigens this entity. In tumors with mutational burden, gene fusions may represent a source tumor-specific neoantigens. Here, we reviewed landscape medulloblastoma and analyzed their predicted immunogenicity. Furthermore, described in-frame fusion protein identified by RNA-Seq. The involved two genes on...
The treatment of relapsed pediatric cancers represents a challenge, also due to possible underlying rare germline mutations. introduction next sequencing technologies allows deeper understanding molecular mechanisms involved in cancer progression helping the identification personalized therapies for these patients. However, most tumors harbor several pathway alterations and it is necessary prioritize options. Here we applied concept therapy patient with an anaplastic ependymoma who three...
10013 Background: In 2006, COG reclassified subgroups of toddlers diagnosed with neuroblastoma from high-(HR) to intermediate-risk (IR), when the age cut-off for increased risk was raised 365 days (12 mo) 547 (18 (London, J Clin Onc 2005). The aim this retrospective study determine if excellent outcome maintained after a reduction therapy. Methods: Children < 3 yrs old at diagnosis, enrolled on biology 1990-2018, were eligible (n = 9,189). Therapy reduced two “cohorts interest” based...
First results of tumor imaging using radiolabelled antibodies date back to 1953. During the last 40 years an improvement this diagnostic procedure was achieved by use monoclonal and new labelling techniques for short-lived isotopes. Up now, three groups patients take advantage immunoimaging, namely with colorectal cancer, ovarian malignant melanoma. In recidivation carcinoma accuracy radioimmunodetection (RID) is approximately 90%. The same holds true cancer; in these cases RID may decrease...